<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396119</url>
  </required_header>
  <id_info>
    <org_study_id>CFTSp178</org_study_id>
    <secondary_id>276443</secondary_id>
    <nct_id>NCT04396119</nct_id>
  </id_info>
  <brief_title>Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study</brief_title>
  <official_title>Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from
      the perspective of survivors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors'
      understanding of cancer screening as a concept and the benefits of screening and early
      detection Explore survivors' level of awareness of and attitudes towards their lung cancer
      risk Explore survivors' views on the barriers and motivating factors that would impact their
      decision to attend a lung cancer screening test
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Explore survivors' attitudes towards lung cancer and lung cancer screening</measure>
    <time_frame>6 months</time_frame>
    <description>Semi-structured interviews</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who have previously been treated for Hodgkin lymphoma without evidence of
        relapse for at least 5 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Details held in the ADAPT database at The Christie NHS Foundation trust

          -  Responded to most recent ADAPT study questionnaire (April - August 2019)

          -  Aged 18-80

          -  Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5
             years

          -  Able to provide informed consent

          -  Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or
             alkylating agent containing chemotherapy.

        Exclusion Criteria:

          -  Previous or current diagnosis of lung cancer

          -  Stated within 2019 health questionnaire that they did not wish to be contacted

          -  Have participated in lung cancer screening through the Manchester Lung Health Checks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Clare Griffin, PhD</last_name>
    <phone>00 44 161 918 7357</phone>
    <email>christiesponsoredresearch@christie.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Broadbent</last_name>
      <email>rachel.broadbent@christie.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not intended to share IPD with other researchers outside the study team</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

